Khalid El Bairi/africanscientists.africa
Jun 8, 2025, 08:48
Khalid El Bairi: Low-Dose anti-PD-(L1) ICIs are also effective and may improve access, especially in resource-limited settings
Khalid El Bairi, Founder of The Cancer Biomarkers Working Group, shared an article on LinkedIn:
“This is our latest publication in the European Journal of Cancer in which we demonstrated that low-dose anti-PD-(L1) immune checkpoint inhibitors are also effective and may improve access, especially in resource-limited settings.
Find more here.”
Expanding Access to Cancer Immunotherapy: A Systematic Review of Low-Dose PD-(L)1 Inhibitor Strategies.
Authors: Pablo Jiménez-Labaig, Failah Mohamed, Nur Jihan Irwan Tan, Ilves Sanna, Khalid El Bairi, Shah Zeb Khan, Amol Akhade, Teresa Amaral, Dario Trapani, Amol Patel, and Kevin J. Harrington.
You can read the full article on European Journal of Cancer.
More posts featuring Khalid El Bairi.
Amol Akhade
Amol Patel
anti-PD-L1
cancer
Cancer Immunotherap
Dario Trapani
European Journal of Cancer
Failah Mohamed
fight against cancer
Global fight against cancer
ICIs
Ilves Sanna
Immune Checkpoint Inhibitors
Kevin J. Harrington.
Khalid El Bairi
Low-Dose PD-(L)1 Inhibitor
Nur Jihan Irwan Tan
OncoDaily
Oncology
Pablo Jiménez-Labaig
Shah Zeb Khan
Teresa Amaral
The Cancer Biomarkers Working Group
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 8, 2025, 10:36
Jun 8, 2025, 10:14
Jun 8, 2025, 10:02
Jun 8, 2025, 09:53